<?xml version="1.0" encoding="UTF-8"?>
<p>Participants between 2 and 6 years of age (median age 4.6 years; range 2.26–5.97) who met criteria for a clinical diagnosis of ASD based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) were included in the study. The DSM‐5 diagnosis of ASD was established by expert clinicians and informed by the Autism Diagnostic Observation Schedule, Second Edition 
 <xref rid="sct312347-bib-0044" ref-type="ref">44</xref> and the Autism Diagnostic Interview, Revised 
 <xref rid="sct312347-bib-0045" ref-type="ref">45</xref>. Additional inclusion criteria included (a) a nonverbal intelligence quotient (NVIQ) of ≥ 35 on the Stanford–Binet Intelligence Scales for Early Childhood, Fifth Edition 
 <xref rid="sct312347-bib-0046" ref-type="ref">46</xref> or Mullen Scales of Early Learning 
 <xref rid="sct312347-bib-0047" ref-type="ref">47</xref>, (b) availability of a qualified autologous umbilical cord blood unit, (c) participant was stable on their current medications for at least 2 months prior to the infusion, (d) ability to travel to Duke University three times (baseline and 6 and 12 months post‐baseline), and (e) parents were English speaking. Exclusion criteria included (a) a history of prior cell therapy, (b) use of intravenous immunoglobulin or other anti‐inflammatory medications (with the exception of non‐steroidal anti‐inflammatory drugs), (c) known genetic (e.g., fragile X) or other significant medical comorbidity, (d) obvious physical dysmorphology suggestive of a genetic syndrome, (e) an uncontrolled seizure disorder, (f) significantly impaired renal or liver function, and (g) clinically significant abnormalities in complete blood count. See Table 
 <xref rid="sct312347-tbl-0001" ref-type="table">1</xref> for baseline characteristics of the sample.
</p>
